Alector Initiates Phase 1 Trial of AL002 for the Treatment of Patients with Alzheimer’s Disease
Go back to Alector Initiates Phase 1 Trial of AL002 for the Treatment of Patients with Alzheimer’s Disease| AbbVie (NYSE: ABBV) | Delayed: 265.08 -0.13 (0.05%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $265.21 | 52 Week High | $68.12 | |||
| Open | $266.00 | 52 Week Low | $50.71 | |||
| Day High | $269.39 | P/E | 57.50 | |||
| Day Low | $263.59 | EPS | $4.61 | |||
| Volume | 3,445,543 | |||||
